SOAT1 and Ehlers-Danlos syndrome, musculocontractural type: Particularly, the JAK-STAT-signaling pathway was activated in this subset of ATCs, and JAK inhibition with ruxolitinib decreased the expression of the JAK-STAT pathway downstream molecules (SOCS3, BCL2L1, and MYC) [60].